Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Tumor markers associated with increased survival in Phase II trial of AV-GBM-1

Daniela Bota, MD, PhD, The University of California, Irvine, Irvine, CA, discusses the tumor markers that were associated with increased survival in the Phase II trial of AV-GBM-1, a dendritic cell vaccine. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.